Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs

Background Genetic polymorphisms are major determinants of individual variability in a drug’s efficacy and safety, which is one of the main challenges in current clinical practice and drug development. The aim of this work was to develop a physiologically based pharmacokinetic (PBPK)/pharmacodynamic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics 2016-08, Vol.55 (8), p.957-969
Hauptverfasser:	Alqahtani, Saeed, Kaddoumi, Amal
Format:	Artikel
Sprache:	eng
Schlagworte:	Central Nervous System Agents - metabolism Central Nervous System Agents - pharmacokinetics Dose-Response Relationship, Drug Fluvoxamine - metabolism Fluvoxamine - pharmacokinetics Humans Internal Medicine Medicine Medicine & Public Health Models, Biological Models, Theoretical Original Research Article Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Polymorphism, Genetic - genetics Predictive Value of Tests Quetiapine Fumarate - metabolism Quetiapine Fumarate - pharmacokinetics Receptors, Neurotransmitter - metabolism Receptors, Neurotransmitter - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!